Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine by Donna M. Graham & Natasha B. Leighl
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MINI REVIEW ARTICLE
published: 22 September 2014
doi: 10.3389/fonc.2014.00258
Economic impact of tissue testing and treatments of
metastatic NSCLC in the era of personalized medicine
Donna M. Graham and Natasha B. Leighl*
Department of Medicine, Division of Hematology and Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Edited by:
Barbara Melosky, British Columbia
Cancer Agency, Canada
Reviewed by:
Alex Zhavoronkov, The Biogerontology
Research Foundation, UK
Meng XuWelliver, The Ohio State
University James Cancer Center, USA
*Correspondence:
Natasha B. Leighl , Department of
Medicine, Division of Hematology
and Oncology, Princess Margaret
Cancer Centre, University of Toronto,
610 University Avenue, Toronto,
Ontario M5G 2M9, Canada
e-mail: natasha.leighl@uhn.ca
A paradigm-shift in the management of non-small cell lung cancer (NSCLC) has resulted in
many new therapies becoming available for patients with advanced disease. Stratification
of treatment by histologic and molecular subtype is recommended to obtain the great-
est clinical benefit for patients while minimizing adverse effects of treatment. However,
these advances in diagnosis and treatment of NSCLC have come at a financial cost. This
review highlights the economic impact of screening for molecular abnormalities and tar-
geted treatment for advanced NSCLC. Major determinants of cost are drug acquisition and
molecular testing. As technologies advance, molecular testing costs may reduce. However,
we must collaborate with payers and manufacturers to ensure that high drug costs do not
limit patient accessibility to potentially beneficial treatment.
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INTRODUCTION
Increasing understanding of the biology of cancer has resulted
in strategies to personalize therapy for patients. In advanced
non-small cell lung cancer (NSCLC), these advances have led to
stratification of treatment by histological and molecular subtype
to obtain the greatest clinical benefit, while minimizing adverse
effects of treatment (1–3). However, these innovations in diagnosis
and treatment of NSCLC have come at a financial cost. Where cure
is not an option, the impact of cost is a significant consideration
in provision of cancer care.
TREATMENT FOR NSCLC
The SWOG 9509 (4) and ECOG 1594 (5) studies established
platinum-based doublet chemotherapy as the treatment of choice
in advanced NSCLC. These studies did not demonstrate benefit
between treatment regimens for any subgroup analyzed. However,
comparison of pemetrexed with docetaxel as second-line therapy
(6), and a subsequent randomized trial comparing the combina-
tion of pemetrexed/cisplatin with gemcitabine/cisplatin as first-
line treatment (7), highlighted a clinical benefit for pemetrexed
in patients with non-squamous histology, giving the first sugges-
tion that NSCLC can no longer be treated as one disease. Further
attempts to improve outcomes included the addition of beva-
cizumab to platinum-doublet chemotherapy. This combination
resulted in hemoptysis when used to treat patients with squamous
cell carcinoma (8), resulting in selective treatment of patients with
non-squamous histology only. A modest survival benefit of two
months was seen in the bevacizumab arm with overall survival of
12.3 months compared with 10.3 months for the chemotherapy
alone arm (9) and 4 months in the adenocarcinoma subgroup.
Further therapeutic options became available with the emer-
gence of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs). The presence of activating mutations in exons
18, 19, 20, and 21 of EGFR in NSCLC [in 15% of adeno-
carcinoma (10)] predicts for improvements in progression-free
survival, response, and quality of life with the use of EGFR
TKIs for this subpopulation of patients compared to traditional
chemotherapy (10–12). In addition, the presence of the echino-
derm microtubule-associated protein-like 4-anaplastic lymphoma
kinase (EML4-ALK ) fusion gene in 2–7% of cases of NSCLC (13)
is a target for therapy with crizotinib with enhanced response
rates and progression-free survival when compared to second-line
chemotherapy in pre-treated patients, and more recently first-line
treatment (3). These targeted therapies have dramatically changed
the diagnosis and treatment of NSCLC.
COSTS OF LUNG CANCER MANAGEMENT
Increasing costs of cancer management are a global issue. The esti-
mated cost of cancer care in the United States (US) was $124.57
billion in 2010, with a minimum estimated cost of lung cancer care
being $12.12 billion. Using the most conservative estimates, this
cost was predicted to increase by 25% to $15.19 billion by 2020
(14). However, this does not account for changes in treatment
strategy and the introduction of novel agents. Canadian data have
shown that the proportion of patients receiving systemic ther-
apy has doubled from 18.1 to 37.5% from 1997 to 2007 but that
the treatment costs tripled during this interval (15). Cost is of
major concern to patients and payors, with medical debt being
the most common cause of personal bankruptcy in the US (16).
Molecularly targeted agents, while providing clinical benefit, carry
a high price tag. The monthly cost of the EGFR TKI erlotinib is
$2,847CAD (Canadian dollars), and the ALK TKI crizotinib costs
$10,400CAD for a month’s supply (17). Additional expenses may
also apply, including overhead costs, within certain countries.
With the expanding use of targeted therapies in this popula-
tion, even greater increases in the cost of lung cancer treatment are
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anticipated. In addition, the cost of further diagnostic testing to aid
treatment selection will escalate costs in the management of lung
cancer. Obtaining value for money when prescribing expensive
medications is critical for patients, payors, and society.
DIAGNOSTIC TESTING
As histology and molecular subtype are such critical determinants
of cancer treatment, adequate tissue sampling is vital. Approxi-
mately 70% of NSCLC is diagnosed at an advanced stage, usually
by small biopsy sampling rather than surgical resection. Interna-
tional guidelines have recommended routine immunohistochem-
ical staining (IHC) of all NSCLC for diagnosis, histologic subtype
and molecular testing for EGFR mutation, and EML4-ALK fusion
for patients with advanced NSCLC (18–20). With small tissue
or cytology samples, the diagnostic yield may be compromised,
resulting in a requirement for re-biopsy to obtain more tissue to
accurately provide a diagnosis. In the IPASS study, 44% of patients
did not have available tissue for molecular testing (12), similar to
55% of patients in the BR.21 study (2). In addition, the tumor
content may be insufficient for molecular testing (21). Amount
of tissue required and labor intensiveness depend on the tech-
niques employed, e.g., IHC requires less tissue and is less costly
than fluorescent in situ hybridization (FISH) or sequencing, cost-
ing $40CAD compared with $388CAD for FISH (22). Therefore,
the availability of tissue and method of testing are of clinical and
economic importance.
Standardized IHC is recommended for diagnosis of NSCLC
and the determination of histologic subtype. The current gold
standard for EML4-ALK testing, used in initial clinical studies as
a companion diagnostic tool, is the use of a break-apart FISH
assay (Vysis ALK Break Apart FISH Probe, Abbott Molecular Inc.,
Des Plaines, IL, USA). However, reverse-transcriptase polymerase
chain reaction, IHC, chromogenic in situ hybridization (CISH),
and other techniques may also be used. The most reliable of these
alternative methods is IHC, due to improved sensitivity and speci-
ficity of the antibodies (23). IHC has been shown to correlate with
FISH in several studies (24, 25), providing a far less costly and more
easily accessible method for preliminary detection of EML4-ALK
fusion, which may subsequently be confirmed with FISH (26).
EGFR mutation testing can be performed using Sanger sequenc-
ing, and other less labor-intensive methods of EGFR mutation
testing have been developed, which may have even greater sensi-
tivity (27, 28). Multiplex assays and next-generation sequencing
in lung cancer samples are tested for several genomic aberrations
simultaneously and usually include EGFR genotyping.
Personalized therapy relies on the presence of a predefined
clinical, pathological, or molecular biomarker. Biomarkers can be
incorporated into drug development by different methods. Where
a biomarker is integral to the drug development process, the popu-
lation are screened and pre-selected for treatment on the presence
of this biomarker. In order for this to be a valid strategy, robust
preclinical data must strongly support this methodology. Crizo-
tinib (an ALK, ROS-1, and MET inhibitor) is an example of a drug
that was developed using an integral approach (29). An a priori
hypothesis of efficacy in patients with EML4-ALK+,ROS-1+, and
MET amplified tumors was used to enroll only these subpopula-
tions to the study. This trial design led to accelerated approval for
this agent, where the relatively low frequency of EML4-ALK in
the population of NSCLC may have otherwise resulted in a nega-
tive outcome. However, there is a concern that this approach may
miss activity in biomarker-negative patients who may potentially
benefit from an agent, if they are excluded from clinical trials. In
addition, the cost of identifying the target population in this type
of study is not accounted for.
Alternatively, a biomarker may be integrated into trial design,
allowing both biomarker-positive and -negative patients to receive
treatment, thereby enabling assessment of benefit in both groups.
In this case, all patients are tested for the presence of the biomarker,
and analysis of the subpopulation of interest occurs retrospec-
tively. This was the case with the EGFR TKIs, where the biomarker
of interest was initially thought to be EGFR protein expression (30)
but pre-specified subgroup analysis confirmed a greater benefit for
this therapy in patients with the presence of EGFR mutation in the
tumor (12, 31–33).
ECONOMIC ANALYSES
Economic analyses aim to contextualize the cost of healthcare ser-
vices by providing a measure of the cost and consequences for
different treatments. The gold standard for oncology is the cost–
utility analysis. Results are commonly presented as incremental
cost-effectiveness ratios (ICER) and cost per quality-adjusted life
year (QALY) to give a measure of the value of the intervention
based on clinical benefit and costs (34). The quality of an eco-
nomic assessment is often driven by the existing clinical data to
support the intervention (35).
Different paths of drug development become important in eco-
nomic analyses when considering the methods by which the inter-
vention in the target population and the comparator is defined.
There are different approaches to evaluate the cost of personalized
medicine. It is possible to focus only on the target population and
compare the intervention with other comparators in that group.
However, the cost of identifying the target population through
molecular testing will not be incorporated in this design, thereby
potentially underestimating total cost of therapy. An alternative
approach would be to compare a strategy of testing for the target
biomarker in the entire population followed by treatment of the
target population, with a strategy involving no biomarker testing
and standard of care therapy. However, this relies on availability
of an accurate assay for biomarker assessment in order to identify
the true target population as a proportion of the population as a
whole. An effect on small target populations may have minimal
change in outcome for the population as a whole, especially if the
target population is very small, e.g., 1–2%. Also, improvements in
technology may result in a change of testing strategy and modified
costs in the future. Another approach may be to separate the test
and treat component of the analysis (26).
EGFR TKIs
These agents were developed before the optimal target population
was defined. Thus, early trials in lung cancer involved unselected
advanced NSCLC patients.
An economic analysis of erlotinib in previously treated other-
wise unselected patients with NSCLC was performed by the NCIC
clinical trials group (NCIC CTG) based on data from the NCIC
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CTG BR.21 study. An ICER of $94,638CAD per life-year gained
(LYG) (95% confidence interval of $52,359–429,148CAD) was
identified (36). Exploratory analysis identified that treating never-
smokers and patients with high tumoral EGFR gene copy number
were the most cost-effective strategies. Interestingly, in patients
with sensitizing EGFR mutations, treatment was associated with
an ICER of $138,168CAD/LYG compared with $87,994CAD/LYG
for patients with EGFR wild-type tumors. This likely reflects the
small survival benefit noted in this study for both groups and
the shorter duration of therapy in patients with EGFR wild-type
tumors.
Over time, we have learned that patients with EGFR-mutated
advanced NSCLC derive the greatest benefit from EGFR TKI ther-
apy, which is superior to chemotherapy in terms of response
rate, quality of life, and progression-free survival, although not
in overall survival due to crossover in clinical trials, with a recent
exception (35). Given this clinical benefit, a number of analy-
ses have been performed to assess cost-effectiveness in this setting
(Table 1). Using platinum-doublet chemotherapy as a comparator,
a CE estimate of £59,216–70,390/QALY was calculated for first-line
gefitinib in a British study (37), but was not considered cost effec-
tive at standard willingness-to-pay thresholds. A number of studies
have also investigated the cost-effectiveness of EGFR TKI treat-
ment with EGFR mutation testing included. Based on the IPASS
study (12), a Singaporean study suggested that first-line treatment
of EGFR-mutated NSCLC with gefitinib was a cost-effective strat-
egy with a CE estimate of $77,160 Singaporean dollars/QALY (38)
compared with carboplatin/paclitaxel, carboplatin/pemetrexed,
or carboplatin/pemetrexed/bevacizumab. Of note, their model
included second-line gefitinib for patients treated with initial
chemotherapy irrespective of EGFR genotype.
The potential for insufficient diagnostic tissue available for
EGFR mutation testing (2, 12) prompted a study in which either
no lung adenocarcinoma patient samples were tested (all received
first-line chemotherapy), a second testing scenario where half of
the patients had sufficient tissue for EGFR testing, or a third sce-
nario where half of the patients had repeat tumor biopsy for EGFR
testing (although 15% still had insufficient tissue after re-biopsy).
First-line erlotinib therapy resulted in an ICER of $110,658/QALY
gain compared with carboplatin/paclitaxel with the testing strategy
and $122,234/QALY using the re-biopsy strategy. With carbo-
platin/pemetrexed as a comparator, the ICER for the repeat biopsy
strategy was $180,665/QALY; adding bevacizumab increased the
ICER significantly to $359,619/QALY, in excess of commonly
accepted thresholds for cost-effectiveness (39). A recent study
from the perspective of the Chinese healthcare system investi-
gated the cost-effectiveness of first-line erlotinib compared with
platinum-doublet chemotherapy in advanced EGFR mutation
positive lung cancer patients based on outcomes from the OPTI-
MAL trial (42). Treatment with upfront erlotinib was deemed
cost effective with an ICER of $85,927.41USD/QALY gained. Of
note, this analysis assumed that after the first 5 months (seven
cycles) of therapy, subsequent erlotinib would be donated by
Roche China.
A U.S. study demonstrated a modest budget impact of EGFR
mutation testing and erlotinib as first-line therapy for patients
with EGFR mutation positive advanced disease compared with
platinum-doublet based chemotherapy regimens, from a U.S.
health plan perspective (43). IncreasingEGFR testing rates from 50
to 100% increased overall health plan expenditures by $0.013 per
member per month (PMPM). Treatment costs contributed $0.012
PMPM with extended duration of treatment giving the greatest
contribution. The cost of EGFR mutation testing was estimated
at $0.002 PMPM, but was offset by the cost-savings associated
with treatment of chemotherapy-related adverse events (−$0.002
PMPM).
Recent clinical data suggest an improvement in progression-
free and overall survival for patients with EGFR-mutant NSCLC
when treated with afatinib compared with platinum-based
chemotherapy (44, 45). Although unable to estimate a plau-
sible ICER based on the manufacturer’s submission, afatinib
was considered to be a reasonable option for first or second-
line treatment for patients with EGFR-mutant NSCLC, with
exploratory estimates from the Evidence Review Committee of
an ICER of £39,300/QALY gained with afatinib compared to
pemetrexed/cisplatin in the overall population, and an ICER of
£23,700/QALY gained in the non-Asian population based on trial
data provided (46).
ALK INHIBITORS
The cost-effectiveness of testing methodology for EML4-ALK
fusion-positive tumors has been assessed using differing tech-
niques, from a societal perspective using the US healthcare
system (26). By varying ALK testing methods and population
tested, the CE of FISH testing for all patients was estimated
at $106,707USD/QALY, compared with $57,165USD/QALY for
IHC. In a clinically selected population of non-smokers with
EGFR- and KRAS-wild type adenocarcinoma, the CE estimates
were $4,756USD/QALY and $2,548USD/QALY for FISH and IHC,
respectively. One cost-effectiveness analysis has explored the use
of crizotinib for the first-line treatment of patients with EML4-
ALK fusion-positive tumors from the Canadian public health-
care perspective (22). The comparator was a platinum-doublet
chemotherapy regimen in patients with non-squamous NSCLC,
and the model incorporated subsequent treatment with peme-
trexed and erlotinib. A re-biopsy strategy was employed in case
of inadequate tissue. The method of assessment for EML4-ALK
positive tumor was by initial IHC and, if positive, confirmatory
testing with FISH. The incremental cost of crizotinib therapy for
a gain of 0.11 QALYs was $2,725CAD/patient, with an ICER of
$255,970/QALY gained. For patients with confirmed EML4-ALK
positive tumors, first-line therapy with crizotinib produced an
ICER of $250,632CAD/QALY, in excess of commonly accepted
cost-effectiveness thresholds. Sensitivity analysis highlighted the
major driver of cost as the price of crizotinib therapy. Despite
FISH testing costs exceeding those of IHC, the relative cost of
crizotinib was so great that use of the cost of initial FISH testing
instead of IHC had minimal impact on the overall ICER.
HISTOPATHOLOGY
Patients with non-squamous NSCLC derive benefit from
pemetrexed-based chemotherapy and from the addition of beva-
cizumab to a platinum-doublet. Although histologic subtype is not
a recognized biomarker, these data have led to treatment selection
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Table 1 | Cost-effectiveness studies of first-line EGFRTKI therapy.
Author Type of study EGFRTKI and
comparator
Model Cost of
testing
Perspective ICER per QALY Cost-
effective?
Remarks
Brown et al.
(37)
Cost-
effectiveness
analysis
Gefitinib compared with
platinum-doublet
chemotherapy
Decision model comparing
gefitinib with carbo/tax in
patients with EGFR mutation
positive disease
No National Health
Service
£59,216–70,390 No Clinical data from IPASS: (12)
de Lima
Lopes et al.
(38)
Cost–utility
analysis
Gefitinib compared with
carbo/gem
Subset analysis of
gefitinib as second-line
Assumed 60% with
EGFR mutation
Decision tree with testing
versus no testing and multiple
lines of treatment.
Test positive: gefitinib,
carbo/gem, BSC
Test negative: Carbo/gem,
BSC
No testing: Carbo/gem,
gefitinib, BSC
Included
$380
Singaporean
health care
system, 2010
Singapore dollars
$77,160 Yes Clinical data from 3 trials: IPASS:
(12);WJTOG 345: (32);
C000000376: (33)
Handorf et al.
(39)
Cost-
effectiveness
analysis
Erlotinib compared with
carbo/tax, carbo/pem,
and carbo/pem/bev
Decision analytic model with
testing versus no testing and
re-biopsy included
Test positive: erlotinib
Test negative: platinum-based
chemotherapy
No testing or insufficient
tissue on repeat biopsy:
platinum-based
chemotherapy
Yes Payer’s
perspective
$110,658 for
carbo/tax test and
treat
$122,234 for
carbo/tax re-biopsy
$180,665 for
carbo/pem
$359,619 for
carbo/pem/bev
Yes Re-biopsy strategy included:
assumed 15% yielded insufficient
tissue
Brown et al.
(40)
Cost-
effectiveness
analysis
Gefitinib compared with
platinum-doublet
chemotherapy
Decision model comparing
gefitinib with cis/tax,
carbo/tax or cis/doc
No UK National
Health Service
and Personal
Social Services
Mean £35,700
(range £59,216–
70,390)
No Clinical data from IPASS: (12, 31);
WJTOG 345: (32); C000000376:
(33); Mean negotiated NHS costs
included
Wang et al.
(41)
Cost-
effectiveness
analysis
Erlotinib compared with
carbo/gem
Markov model comparing
carbo/gem for 4 cycles with
erlotinib until progression
No Chinese health
care system,
2010 US dollars
$85927.41 (range
$58,584.57–
336,404.20)
Yes Clinical data from OPTIMAL trial:
(42)
Cost of erlotinib included only for
first 7 cycles (from cycle 8 or
month 5 onward cost is zero due
to donations from Roche China)
EGFR TKI, epidermal growth factor tyrosine kinase inhibitor; ICER, incremental cost-effectiveness ratio; LY, life years; QALY, quality of life year; carbo/gem, carboplatin and gemcitabine chemotherapy; BSC, best
supportive care; carbo/tax, carboplatin and paclitaxel; carbo/pem, carboplatin and pemetrexed; carbo/pem/bev, carboplatin, pemetrexed and bevacizumab; cis/tax, cisplatin and paclitaxel; cis/doc, cisplatin and
docetaxel.
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for patients based on histologic subtype. Given the significant cost
of these agents when compared with other standard chemotherapy
regimens, several economic assessments have been performed. A
cost–utility analysis of the addition of bevacizumab to platinum-
based chemotherapy compared with chemotherapy alone (9) in
patients with non-squamous NSCLC estimated an increase of 0.13
QALYs with the addition of bevacizumab, at a cost of $72,000USD
per patient. The incremental cost–utility ratio for the addition of
bevacizumab was $560,000USD/QALY (47), exceeding accepted
thresholds for cost-effectiveness.
In the first-line setting, pemetrexed/cisplatin improved median
overall survival by 1 month in advanced non-squamous lung
carcinoma patients, when compared with gemcitabine/cisplatin,
and an ICER estimated at £17,000–25,000/QALY (48). When
pemetrexed is used as maintenance, the median survival gain
compared to observation is 5 months, with an ICER of $122,
371USD/LYG.
CONCLUSION
The management of lung cancer has transformed in recent years,
due to increasing stratification of treatment based on pathologic
and molecular characteristics. Optimizing treatment by using per-
sonalized therapy has resulted in improved treatment responses,
quality of life, and progression-free survival of patients with
NSCLC, with some evidence of survival benefit. However, this
comes at a price, and, acknowledging that these actionable muta-
tions are present only in a small subset of NSCLC tumors, we
must act in the best interests of all our patients to ensure that this
is affordable for the benefit gained.
In order to focus on the relevant population for a molecularly
targeted therapy, tissue must be available and the testing method
must be accurate. However, as in the case of EML4-ALK, there
may be methods to select the target population with lower cost,
and these technologies will continue to evolve. Further evolution
of next-generation sequencing and multiplex platforms may also
improve the cost-effectiveness of testing, where multiple abnor-
malities can be evaluated with a single test. While molecular testing
beyond EGFR andALK is not currently recommended as standard
of care in NSCLC (18), more comprehensive genomic testing will
likely become cheaper and more accessible in the future, minimiz-
ing time and tissue requirements in efforts to better personalize
therapy (49, 50).
Cost-effective, -accurate, and -efficient methods of diagnosis
must be employed, which allow equal accessibility to therapy for
all patients. However, the major cost determinant in most eco-
nomic evaluations of targeted treatment in NSCLC is drug price.
Economic evaluations are integral to assessment of value for a
given therapy as these may be used to enable funding decisions
by policy-makers, and to negotiate pricing strategies with manu-
facturers where possible. There has been a paradigm-shift in the
treatment of NSCLC with exciting new therapies revolutionizing
treatment for patients with a previously dismal prognosis. As clin-
icians, we must ensure that as many patients as possible derive
benefit from a personalized approach. Collaboration with payers
and manufacturers is a key to ensure that cost of treatment is not
prohibitive for patients and permitting further advances in lung
cancer therapy.
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